Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer
Rebecca B Riggins1, Amy H Bouton, Minetta C Liu
1Department of Oncology and Physiology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Abstract:
Antiestrogens have been the therapeutic agents of choice for breast cancer patients whose tumors express estrogen receptors, regardless of menopausal status. Unfortunately, many patients will eventually develop resistance to these drugs. Antiestrogens primarily act by preventing endogenous estrogen from activating estrogen receptors and promoting cell growth, which can ultimately lead to tumor cell death. Understanding the mechanisms by which antiestrogens cause cell death or apoptosis is critical to our efforts to develop ways to circumvent resistance. This article focuses on antiestrogen-induced apoptosis both in vitro and in vivo. We review the clinical utility of both antiestrogens and aromatase inhibitors and their apoptogenic mechanisms in cell culture models. Among the key signaling components discussed are the roles of Bcl-2 family members, several cytokines, and their receptors, p53, nuclear factor kappa B (NFkappaB), IRF-1, phosphatidylinositol 3-kinase (PI3K)/Akt, and specific caspases. Finally, we discuss the evidence supporting a role for apoptotic defects in acquired and de novo antiestrogen resistance.
Insights
Antiestrogens induce apoptosis in estrogen receptor-positive breast cancer cells. Understanding these cell death mechanisms is key to overcoming drug resistance in patients.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Antiestrogens are crucial for estrogen receptor-positive breast cancer treatment.
- Therapeutic resistance to antiestrogens is a significant clinical challenge.
- Apoptosis induction by antiestrogens is a key mechanism of action.
Purpose of the Study:
- To review antiestrogen-induced apoptosis in vitro and in vivo.
- To explore the molecular mechanisms underlying antiestrogen efficacy.
- To discuss the role of apoptotic defects in antiestrogen resistance.
Main Methods:
- Review of clinical utility of antiestrogens and aromatase inhibitors.
- Analysis of apoptogenic mechanisms in cell culture models.
- Discussion of signaling pathways involved in apoptosis.
Main Results:
- Key signaling components include Bcl-2 family, cytokines, p53, NFkappaB, IRF-1, PI3K/Akt, and caspases.
- Evidence suggests apoptotic defects contribute to acquired and de novo resistance.
- Antiestrogens trigger cell death pathways critical for tumor control.
Conclusions:
- Understanding antiestrogen-induced apoptosis is vital for overcoming resistance.
- Targeting apoptotic pathways may offer new therapeutic strategies.
- Defects in apoptosis are implicated in treatment failure for breast cancer.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Related Concept Videos
Drugs that Stabilize Microtubules
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Apoptosis
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
